IN-PART, a technology company that brings together universities and businesses across the globe, today announced that following successful beta testing, it is launching a new, bespoke scouting service for R&D professionals, called IN-PART: Discover. The new service will revolutionise open innovation by providing companies with novel opportunities for collaboration, specific to their requirements, and often unseen elsewhere.
30 October, 2017
The topic of this month’s newsletter from Drug Discovery Today is “nanoscience in drug discovery”
26 October, 2017
Medicines Discovery Catapult and ANTRUK Enterprises initiate joint research project
19 October, 2017
A new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’, has been discovered through an alliance between industry and academia created by Cancer Research UK.
18 October, 2017
THE biggest UK life sciences delegation to head to Japan in ten years was in Tokyo on the 10th October to showcase the sector’s strengths and foster collaborations; led by regional cluster organisations MedCity and the Northern Health Science Alliance (NHSA), with the Department for International Trade.
18 October, 2017
A nine-year joint research project conducted by VIB, KU Leuven and VUB has led to a crucial breakthrough in cancer research. Scientists have clarified how the Warburg effect, a phenomenon in which cancer cells rapidly break down sugars, stimulates tumor growth. This discovery provides evidence for a positive correlation between sugar and cancer, which may have far-reaching impacts on tailor-made diets for cancer patients. The research has been published in the leading academic journal Nature Communications.
17 October, 2017
A powerful new way of analysing how drugs interact with molecules in the body could aid the design of better treatments with fewer side-effects.
08 October, 2017
Alderley Park, England, and Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) and AMR Centre Ltd (AMRC) 5th October, announce signing of an agreement providing AMRC the exclusive worldwide rights to Medivir’s research stage metallo-ß-lactamase inhibitor (MBLI) program.
07 October, 2017
Board hears update on preparations for Brexit and adopts Agency’s mid-year report
06 October, 2017